Insmed falls 18.7% as Arikace disappoints
This article was originally published in Scrip
Executive Summary
Insmed's once-daily Arikace (liposomal amikacin for inhalation) met the primary endpoint of non-inferiority to Novartis's twice-daily TOBI (tobramycin inhalation solution) in the treatment of Pseudomonas aeruginosa (Pa) in cystic fibrosis (CF) patients in a Phase III study.